This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TERN Terns Pharmaceuticals (TERN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipTrendsBuy This Stock About Terns Pharmaceuticals Stock (NASDAQ:TERN) Get Terns Pharmaceuticals alerts:Sign Up Key Stats Today's Range$52.94▼$52.9850-Day Range$42.00▼$53.1752-Week Range$2.65▼$53.19Volume6.35 million shsAverage Volume4.84 million shsMarket Capitalization$6.12 billionP/E RatioN/ADividend YieldN/APrice Target$55.14Consensus RatingHold Company Overview Terns Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies. The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation. These include inhibitors of key pathways implicated in nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), as well as programs directed at hepatocellular carcinoma. Each candidate is being investigated for its ability to modulate disease drivers such as bile acid metabolism, immune cell activation and cell‐signaling cascades involved in fibrosis. Terns leverages state‐of‐the‐art medicinal chemistry and translational biology platforms to optimize both efficacy and safety profiles across its portfolio. Headquartered in San Diego, California, Terns Pharmaceuticals operates in a hub known for innovation in hepatology and liver disease research. The company’s management and scientific leadership bring extensive experience from established biotech and pharmaceutical organizations, with deep expertise in clinical development, regulatory strategy and commercialization planning. By combining this leadership team’s industry knowledge with strategic partnerships and academic collaborations, Terns is positioned to advance its therapeutic candidates toward regulatory milestones and, ultimately, broaden treatment options for patients suffering from severe liver diseases.AI Generated. May Contain Errors. Read More Receive TERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TERN Stock News HeadlinesHow The Merck (MRK) Investment Story Is Shifting With Terns Deal And Oncology UpdatesMay 18, 2026 | finance.yahoo.comMerck Completes Acquisition of Terns Pharmaceuticals, Inc.May 5, 2026 | businesswire.comEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - and much of it sits beneath the desert near the Grand Canyon. A drilling crew just hit the DOE's 2035 targets twelve years early, with costs down 50% in 18 months. Google signed on, Gates invested, and the Pentagon made it a priority. One company has been quietly building this infrastructure for sixty years.July 4 at 1:00 AM | Behind the Markets (Ad)Merck still sees ‘compelling’ outlook for Terns leukemia drugApril 30, 2026 | finance.yahoo.comOppenheimer downgrades Terns Pharmaceuticals (TERN)April 28, 2026 | msn.comTerns Pharmaceuticals gets FDA breakthrough status for leukemia drugApril 27, 2026 | investing.comTerns Pharmaceuticals Gets Breakthrough Designation for Leukemia TreatmentApril 27, 2026 | marketwatch.comTerns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid LeukemiaApril 27, 2026 | globenewswire.comSee More Headlines TERN Stock Analysis - Frequently Asked Questions How were Terns Pharmaceuticals' earnings last quarter? Terns Pharmaceuticals, Inc. (NASDAQ:TERN) announced its earnings results on Monday, March, 30th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.06. When did Terns Pharmaceuticals IPO? Terns Pharmaceuticals (TERN) raised $120 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO. What other stocks do shareholders of Terns Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Terns Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX). Company Calendar Last Earnings3/30/2026Today7/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 TERN's financial health is in the Green zone, according to TradeSmith. TERN has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TERN CIK1831363 Webwww.ternspharma.com Phone650-525-5535FaxN/AEmployees40Year Founded2017Price Target and Rating Average Price Target for Terns Pharmaceuticals$55.14 High Price Target$70.00 Low Price Target$44.50 Potential Upside/Downside+4.1%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$96.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-20.02% Return on Assets-19.37% Debt Debt-to-Equity RatioN/A Current Ratio62.41 Quick Ratio62.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.70 per share Price / Book5.46Miscellaneous Outstanding Shares115,520,000Free Float113,788,000Market Cap$6.12 billion OptionableNot Optionable Beta-0.37 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:TERN) was last updated on 7/4/2026 by MarketBeat.com Staff. From Our PartnersHe turned $12,415 into millions. Now he wants to help you.Tim Sykes turned $12,415 in bar mitzvah money into over $7 million in trading profits - and more than 50 of hi...Tim Sykes | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | Sponsored4th of July Chaikin flash saleMarc Chaikin - the 60-year Wall Street veteran who called Nvidia before it surged 45,000% - is running his fir...Chaikin Analytics | SponsoredGold to $4,900—Here’s the Real PlayGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredI have $2.3M saved for retirement. How much can I actually spend each year?If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredThe startup growing 23 times faster than NvidiaAn official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
